Conflicts of interest S.P.L. is employed by Alliance Boots Ltd., the manufacturer of the commercially available preparation tested in this study.
A cosmetic ‘anti-ageing’ product improves photoaged skin: a double-blind, randomized controlled trial
Article first published online: 28 APR 2009
© 2009 Boots Company Plc
British Journal of Dermatology
Volume 161, Issue 2, pages 419–426, August 2009
How to Cite
Watson, R.E.B., Ogden, S., Cotterell, L.F., Bowden, J.J., Bastrilles, J.Y., Long, S.P. and Griffiths, C.E.M. (2009), A cosmetic ‘anti-ageing’ product improves photoaged skin: a double-blind, randomized controlled trial. British Journal of Dermatology, 161: 419–426. doi: 10.1111/j.1365-2133.2009.09216.x
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2·5, which does not permit commercial exploitation.
Note added after online publication:
Since the publication of this article online on 28 April 2009, the authors wish to recognize the following changes to the article:
Title: Effects of a cosmetic ‘anti-ageing’ product on photoaged skin
Conflicts of Interest: This study was funded by Alliance Boots Ltd.
Methods For the patch test, commercially available test product and its vehicle were applied occluded for 12-days to photoaged forearm skin (n = 10) prior to biopsy and immunohistochemical assessment of fibrillin-1; all-trans retinoic acid (RA) was used as a positive control. Sixty photoaged subjects were recruited to the RCT (test product, n = 30 vs. vehicle, n = 30; once daily for 6-months; face & hands) with clinical assessments performed at recruitment and following 1-, 3- & 6-months of use. Twenty-eight subjects had skin biopsies (dorsal wrist) at baseline and at 6 months of treatment for immunohistochemical assessment of fibrillin-1 (test product, n = 15; vehicle, n = 13). All subjects received test product for a further 6-months. Final clinical assessments were performed at the end of this open period; 27 subjects received test product for 12-months.
Results In the 12-day patch test assay, we observed significant immunohistological deposition of fibrillin-1 in skin treated by test product and RA as compared to untreated baseline (P = 0·005 and 0·015 respectively). In the clinical RCT, at 6 months, compared to baseline assessment, 43% of subjects on test product had an improvement in facial wrinkles (P = 0·013), whereas only 22% of subjects using vehicle had clinical improvement (P = ns). Between group comparison of test product and vehicle was non-significant (P = 0·10). After 12 months, there was a significant benefit of test product over that projected for vehicle (70% vs. 33% of subjects improving; combined Wilcoxon rank tests, P = 0·026). There was significant deposition of fibrillin-1 in skin treated for 6 months with test product (mean ± SE; vehicle, 1·84 ± 0·23; test product, 2·57 ± 0·19; P = 0·019).
Conclusion An over-the-counter cosmetic ‘anti-ageing’ product demonstrated clear benefit over vehicle in fibrillin-1 deposition over a 6-month trial period. There was a corresponding but non-significant trend towards clinical improvement in facial wrinkles. Clinical improvements in the treated group were increased after a further 6-months of use. This study demonstrates that a cosmetic may improve the appearance of wrinkles and further supports the use of fibrillin-1 as a robust biomarker for repair of photoaged dermis.
- Issue published online: 21 JUL 2009
- Article first published online: 28 APR 2009
- Accepted for publication 3 April 2009
This article has been cited by:
- 2Age-Related Tissue Stiffening: Cause and Effect, Advances in Wound Care, 2013, 2, 1, 11,
- 6Comparisons against baseline within randomised groups are often used and can be highly misleading, Trials, 2011, 12, 1, 264, ,
- 8Molecular aspects of skin ageing, Maturitas, 2011, 69, 3, 249, , ,